2023:
The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance. Marie-Claire Fitzgerald, Philip J O’Halloran, Sean A Kerrane, Triona Ní Chonghaile, Niamh MC Connolly, Brona M Murphy. Cell Death and Disease 14;10 705 2023.
First-in-class metallo-PROTAC as an effective degrader of select Pt-binding proteins. P O’Dowd, GP Sullivan, D Rodrigues, TN Chonghaile, DM Griffith. Chemical Communications
Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC . Zhang H., Nabel C.S, Li D., O’Connor R.I, Crosby C.R, Chang S.M, Hao Y., Stanley R., Sahu S., Levin D.S, Chen T., Tang S Huang H., Meynardie M., Stephens J.,Sherman F., Chafitz A., Costelloe N., Rodrigues D.A, Fogarty H., Kiernan M.G, Cronin C , Papadopoulos E., Ploszaj M., Weerasekara V., Deng J., Kiely P, Bardeesy N., Vander Heiden M.G Ni Chonghaile T, Dowling C.M, Wong K.W. Journal of Thoracic Oncology 18;4 2023.
2022:
The path to venetoclax resistance is paved with mutations, metabolism, and more. Sullivan G.P, Flanagan L., Rodrigues D.A, Ní Chonghaile T. Science Translational Medicine 14;674 2022.
A trans-Pt (II) hedgehog pathway inhibitor complex with cytotoxicity towards breast cancer stem cells and triple negative breast cancer cells. Ryan A.L, Northcote-Smith J., McKeon A., Roe A., O’Dowd P., Twamley B., Ní Chonghaile T., Suntharalingam K., Griffith D.M. Dalton Transactions 2022.
Jak3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Bodaar A., Yamagata N., Barthe A., Landrigan J., Ní Chonghaile T., Burns M., Stevenson K.E., Devidas M., Loh M.L, Hunger S.P, Wood B., Silverman L. B., Teachey D. T., Meijerink J.P., Letai A., Gutierrez A. Leukemia 2022.
Advances in the Design and Development of PROTAC-mediated HDAC Degradation. Rodrigues D.A, Roe A., Griffith D., Ní Chonghaile T. Current Topics in Medicinal Chemistry Vol 22; No. 5 2022.
2021:
Functional precision profiling: The way forward for personalised medicine. Flanagan L., Glavey S., Ní Chonghaile T. J Clinical Hematology Vol 2; Issue 3 2021
The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL. Di Grande A, Peirs S, Donovan PD, Van Trimpont M, Morscio J, Lintermans B, Reunes L, Vandamme N, Goossens S, Nguyen H.A, Lavie A, Lock R.B, Prehn JHM, Van Vlierberghe P# and Ní Chonghaile T# Blood Advances. Vol 5, No7; April 2021.
Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer Dowling C.M, Hollinshead K.E.R, Di Grande A, Pritchard J, Zhang, H, Dillon E.T, Haley K, Papadopoulos E., Mehta A.K, Bleach R,Lindner A.U, Mooney B, Düssmann H, O’Connor D, Prehn J.H.M, Wynne W., HemannM, Bradner J.E, Kimmelman A.C, Guerriero J.L, Cagney G, Wong K.K, Letai A.G, Ní Chonghaile T. Science Advances. Vol 7, No3; January 2021.
Shining a light on metabolic vulnerabilities in non-small cell lung cancer. ,
2020:
A functional genomic screen identifies the deubiquitinase USP11 as a novel transcriptional regulator of ERα in breast cancer. , , , , ,, , ,, , , , , , , and
Secondary plasma cell leukemia treated with single agent venetoclax. Glavey S, Flanagan L, Bleach R, Kelly C, Quinn J, Ni Chonghaile T*, Murphy P*. British Journal of Hematology. June 2020
2019:
BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer. Walsh L, Haley KE, Moran B, Mooney B, Tarrant F, Madden SF, Di Grande A, Fan Y, Das S, Rueda OM, Dowling CM, Varešlija D, Chin S-F, Linn SC, Young LS, Jirström K, Crown J, Bernards R, Caldas C, Gallagher WM, O’Connor DP, Ní Chonghaile T. Clinical Cancer Research. Aug 2019.
The Anti-inflammatory Compound Candesartan Cilexetil Improves Neurological Outcomes in a Mouse Model of Neonatal Hypoxia. Quinlan S, Merino-Serrais P, Di Grande A, Dussmann H, Prehn JHM, Ní Chonghaile T, Henshall DC, Jimenez-Mateos EM. Front. Immunol., Jul 2019.
BH3 mimetic weapons of cancer cell destruction Ní Chonghaile T. Science Translational Medicine. Jan 2019.
2018:
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia Ariës IM*, Bodaar K*, Karim S.A*, Ní Chonghaile T*, Hinze L, Burns M.A, Pfirrmann M, Degar J., Landrigan J.T, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson K.E, Neuberg D.S, Devidas M, Loh M.L, Hunger S.P, Teachey D.T, Rabin K.R, Winter S.S, Dunsmore K.P, Wood B.L, Silverman L.B, Sallan S.E, VanVlierberghe P, Orkin SH, Knoechel B, Letai A.G, Gutierrez A. Journal Of Experimental Medicine. Dec 2018.
Illuminating Aurora Dependencies Ní Chonghaile T. Science Translational Medicine. Nov 2018.
Identifying and targeting residual leukemic cells Ní Chonghaile T. Science Translational Medicine. Sep 2018.
Patient Derived Organoids: are PDOs the new PDX? Ní Chonghaile T. Science Translational Medicine. Jul 2018.
Ironing out dedifferentiation in melanoma Ní Chonghaile T. Science Translational Medicine. May 2018.
Fighting leukemia with “duel”-targeted therapy. Ní Chonghaile T. Science Translational Medicine. April 2018.
Deadly role of chromosomal instability in metastasis Ní Chonghaile T. Science Translational Medicine. Feb 2018.
2017:
Therapeutic rationale to target highly expressed CDK7 conferring poor outcomes in triple-negative breast cancer Li B*, Chonghaile TN*, Fan Y, Madden SF, Klinger R, O’Connor AE, Walsh L, O’Hurley G, Udupi GM, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn S, Jirstrom K, Caldas C, O’Connor DP, Gallagher WM. Cancer Research. Jul 2017.
The emerging role of non-traditional ubiquitination in oncogenic pathways Dwane L, Gallagher WM, Chonghaile TN, O’Connor DP. Journal Of Biological Chemistry. Mar 2017.
2016:
Big Data–Led Cancer Research, Application, and Insights Brown JAL, Chonghaile TN, Matchett KB, Lynam-Lennon N, Kiely PA. Cancer Research. Nov 2016.
Diagnostic and therapeutic implications of histone epigenetic modulators in breast cancer Walsh L, Gallagher WM, Oconnor DP, Ní Chonghaile T. Expert Review of Molecular Diagnostics. May 2016.
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, Richardson P, Anderson K, Amiot M, Letai A. Leukemia. Mar 2016.
2015:
MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199 Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose LK, O’Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O’Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. Cell Reports. Dec 2015.
Targeting the miR-221–222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z, Jiang M, Chen M, Wang X, Kang Y, Zhou Y, Chonghaile TN, Johncilla ME, Tai YT, Cheng JQ, Letai A, Munshi NC, Anderson KC, Carrasco RD. Cancer Research. Oct 2015.
BCL-2 modulates the unfolded protein response by enhancing splicing of X-box binding protein-1 Chonghaile TN, Gupta S, John M, Szegezdi E, Logue SE, Samali A. Biochemical and Biophysical Research Communications. Oct 2015.
2014:
Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts Suryani S, Carol H, Chonghaile TNI, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, Jones L, Manesh DMO, Kurmasheva RT, Billups C, Kaplan W, Letai A, Bourquin JP, Houghton PJ, Smith MA, Lock RB. Clinical Cancer Research. Sep 2014.
Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199 Ní Chonghaile T, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A. Cancer Discovery. Sep 2014.
2013:
Mitochondria: gatekeepers of response to chemotherapy Sarosiek KA, Ni Chonghaile T, Letai A. Trends in Cell Biology Discovery. Dec 2013.
2012:
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, Patton JT, Maiso P, Monrose V, Sacco A, Ngo HT, Flores LM, Lin CP, Magnani JL, Kung AL, Letai A, Carrasco R, Roccaro AM, Ghobrial IM. Blood. Feb 2012.
2011:
Who Put the” A” in Atg12: Autophagy or Apoptosis? Chonghaile TN, Letai A. Molecular Cell Biology. Dec 2011.
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy Chonghaile TN, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore VDG, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, DeAngelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A. Science. Nov 2011.
2009
Mimicking the BH3 domain to kill cancer cells. Chonghaile TN, Letai A. Oncogene. Jul 2009.
Bcl-2 family on guard at the ER . Szegezdi E, MacDonald DC, Chonghaile TN, Gupta S, Samali A. Am. J. of Physiol. May 2009.
2007
Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl‐xL. Reeve JLV, Szegezdi E, Logue SE, Chonghaile TN, O’Brien T, Ritter T, Samali A. J. Cell Mol. Med. July 2007.
2006
Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-XL. Ní Chonghaile T, Concannon CG, Szegezdi E, Gorman AM, Samali A. Apoptosis. Jul 2006.
Targeted Therapeutics in Cancer 